


MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Front Range Mobile Imaging, LLC</p> <p>2. 418 East College Drive Cheyenne, WY 82007</p>	<p>In accordance with application dated May 20, 2025,</p>	<p>4. Expiration Date: June 30, 2034</p>
	<p>3. License No.: 49-29310-01 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-37854 Reference No.:</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p>



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 49-29310-01

Docket or Reference No.:
030-37854

Amendment No. 17

CONDITIONS

10. A. Licensed material may be stored at the licensee's facilities located at 418 East College Drive, Cheyenne, Wyoming, 82007.
- B. Licensed material may be used at the licensee's facilities located at temporary job sites of the licensee anywhere in the United States where the U.S. Nuclear Regulatory Commission maintains jurisdiction for regulating the use of licensed material, including areas of exclusive Federal jurisdiction within Agreement States.

If the jurisdiction status of a Federal facility within an Agreement State is unknown, the licensee should contact the Federal agency controlling the job site in question to determine whether the proposed job site is an area of exclusive Federal jurisdiction. Authorization for use of radioactive materials at job sites in Agreement States not under exclusive Federal jurisdiction shall be obtained from the appropriate State regulatory authority.

11. Licensed material incident to mobile nuclear medicine activities may be delivered to the licensee's mobile van located at temporary job sites when trained licensee personnel are present to receive the licensed material.
12. A. The Radiation Safety Officer (RSO) for this license is John L. Mastin.
- B. The Associate Radiation Safety Officer (ARSO) for this license is Audrey Malloy, for 10 CFR 35.100 and 10 CFR 35.200.
13. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized Users

Bruce A. Berkowitz, M.D.

Material and Use

35.100; 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**


License No.: 49-29310-01

Docket or Reference No.:
030-37854

Amendment No. 17

Authorized UsersMaterial and Use

David K. Bigelow, M.D.	35.100; 35.200
John R. Bodenhamer, M.D.	35.100; 35.200
Donald W. Cain, M.D.	35.100; 35.200
Joseph M. Carabetta, M.D.	35.100; 35.200
Kenneth K. Cicuto, M.D.	35.100; 35.200
Jamie S. Colonnello, M.D.	35.100; 35.200
Nicholas J. Constantine, M.D.	35.100; 35.200
Winfield M. Craven, M.D.	35.100; 35.200
Jason P. Doye, M.D.	35.100; 35.200
Thomas R. Dunphy, M.D.	35.100; 35.200
Gabriel Edwards, M.D.	35.100; 35.200
Michael J. Geraghty	35.100; 35.200
Shaun J. Gonda, M.D.	35.100; 35.200
Neil Grey, M.D.	35.100; 35.200
Deborah Z. Gunderson, M.D.	35.100; 35.200
Christopher Sean Haling, M.D.	35.100; 35.200
S. A. Hayden, M.D.	35.100; 35.200
Amy S. Hayes, M.D.	35.100; 35.200
Mark E. Howshar, M.D.	35.100; 35.200
Eric B. Hoyer, M.D.	35.100; 35.200
J. G. Hubbard, M.D.	35.100; 35.200
Sarah Jess, M.D.	35.100; 35.200
Robert Paul Jones, M.D.	35.100; 35.200
Alistair Jordan, D.O.	35.100; 35.200



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 49-29310-01

Docket or Reference No.:
030-37854


Amendment No. 17

Authorized Users

D. M. Kellam, M.D.
William D. Ketcham II, M.D.
James R. LaManna, M.D.
Joseph J. Lawrence, D.O.
Karl E. Magsamen, M.D.
Frederick Matti, M.D.
Jacob J. Merrell, M.D.
Alan L. Mitchell, M.D.
Justin Monroe, M.D.
Richard J. Pacini, M.D.
Steven H. Peck, M.D.
Daniel R. Possehn, D.O.
Paul W. Rigsby, D.O.
Nicholas Statkus, M.D.
William Byron Taylor III, M.D.
Stanley W. Weinstein, M.D.
Jeffrey R. Weissmann, M.D.
J. W. Wright, M.D.

Material and Use

35.100; 35.200
35.100; 35.200
35.100; 35.200
35.100; 35.200
35.100; 35.200
35.100; 35.200
35.100; 35.200
35.100; 35.200
35.100; 35.200
35.100; 35.200
35.100; 35.200
35.100; 35.200
35.100; 35.200
35.100; 35.200
35.100; 35.200
35.100; 35.200
35.100; 35.200
35.100; 35.200



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 49-29310-01

Docket or Reference No.:
030-37854

Amendment No. 17

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated December 20, 2018 (ML19004A483)
- B. Letter received on October 8, 2019 (ML19303B367)
- C. Letter dated August 12, 2021 (ML21258A084)
- D. Letter dated March 2, 2022 (ML22187A266)
- E. Application dated June 16, 2022 (ML22186A059)
- F. Email dated July 26, 2024 with attachments (ML24211A168)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: August 18, 2025By: _____
Samantha Everett
Region 4